-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
JNJ delivered solid Q1 2026 results with sales growth of 9.9% Y/Y to $24.1B, beating expectations. Adjusted EPS of $2.70 declined from $2.77 prior year but exceeded consensus estimate of $2.68. Strong oncology execution drove Innovative Medicine growth of 11.2% Y/Y to $15.4B, with key Oncology drugs, DARZALEX achieving $4.0B (+22.5% Y/Y) and CARVYKTI reaching $597M (+62.1% Y/Y), helping offset STELARA erosion ($656M, -59.7% Y/Y), as biosimilar competition intensified. Management raised the 2026 guidance to $100.8B sales and $11.55 adjusted EPS, reflecting confidence in the growth trajectory, in our view. We think JNJ's robust pipeline, including key Q1 approvals like ICOTYDE the first-line oral treatment for plaque psoriasis, positions the company well for its transformation into a higher-growth enterprise. With strong franchise execution and multiple growth drivers across oncology and MedTech, we believe JNJ can navigate near-term headwinds while delivering on its path to double-digit growth by decade-end.